C
Compass Therapeutics, Inc. (CMPX)
NCM – Real Time Price. Currency in USD
5.21
-0.12 (-2.25%)
At close: Mar 27, 2026, 4:00 PM EDT
5.29
+0.08 (1.54%)
After-hours: Mar 27, 2026, 6:39 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
5.21
-0.12 (-2.25%)
At close: Mar 27, 2026, 4:00 PM EDT
5.29
+0.08 (1.54%)
After-hours: Mar 27, 2026, 6:39 PM EDT
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
| Name | Position |
|---|---|
| Anna Gifford | Communications Manager |
| Dr. Cynthia A. Sirard M.D. | Chief Medical Officer |
| Dr. James Kranz Ph.D. | VP and Head of Chemistry Manufacturing & Controls |
| Dr. Thomas J. Schuetz M.D., Ph.D. | CEO & Vice Chairman |
| Mr. Arjun Prasad M.B.A., M.P.H. | Chief Commercial Officer |
| Mr. Barry Shin J.D., M.B.A. | Chief Financial Officer |
| Mr. Bing Gong Ph.D. | Chief Scientific Officer |
| Mr. Jonathan E. Anderman J.D. | Senior VP, General Counsel & Corporate Secretary |
| Mr. Neil L. Lerner CPA | Senior VP & Chief Accounting Officer |
| Ms. Karin Herrera B.A. | Senior VP & Head of Clinical Operations |
| Date | Type | Document |
|---|---|---|
| 2026-03-12 | S-8 | d110919ds8.htm |
| 2026-03-05 | 10-K | cmpx20251231_10k.htm |
| 2026-01-06 | 8-K | f8k_010626.htm |
| 2025-12-31 | DEL AM | d26360ddelam.htm |
| 2025-12-30 | S-3 | d26360ds3.htm |
| 2025-11-05 | 10-Q | cmpx20250930_10q.htm |
| 2025-08-13 | 8-K | d153873d8k.htm |
| 2025-08-11 | 8-K | f8k_080925.htm |
| 2025-06-12 | 8-K | f8k_061225.htm |
| 2025-05-08 | 8-K | f8k_050725.htm |